Monthly Archives: May 2017
StatPearls Question of the Week – #5
In the recent clinical trials involving Chimeric Antigen Receptor T cell therapy (CAR-T), which complication led to a halt in the studies?
A. Myocardial...
Targeting Adenosine 2A Receptors Enhances CAR T-Cell Efficacy
February 6, 2017 (The Journal of Clinical Investigation)
Part of the reason why treatment of solid tumors using CAR T-cells has been troublesome is because...
Universal CAR T-Cell Therapy Helped Treat ALL in Two Infants
January 26, 2017 (HealthDay News)
Modified T cells from healthy donor allowed infants to reach remission, researchers report
Two infants with B-cell acute lymphoblastic leukemia (ALL)...
Antibody That Precisely Targets T Cells Discovered
May 22, 2017 (Medical News Today)
An antibody originally developed to study multiple sclerosis has been found to precisely target T cells that can kill...
StatPearls Question of the Week – #4
On which malignancies is Chimeric Antigen Receptor T-cell therapy (CAR-T) being tested?
A. Solid tumors
B. Hematological malignancies
C. Sarcomas
D. Skin cancers
Click...
CAR-T Cell Therapy HCP Guide – KTE-C19 Studies – Zuma 6 Trials
CAR T-Cell Therapy and Checkpoint Inhibitors Together?
CAR T-cell therapy positive response rates in aggressive leukemias and lymphomas are impressive, but relapse or progression does...
CAR-T Cell Therapy HCP Guide – KTE-C19 Studies – Zuma 3 & 4 Trials
CAR T-Cell Therapy for ALL
Axicabtagene ciloleucel (KTE-C19) is also being investigated in the ZUMA-3 and ZUMA-4 trials for treatment of relapsed/refractory acute lymphoblastic leukemia...
CAR-T Cell Therapy HCP Guide – KTE-C19 Studies – Zuma 2 Trials
ZUMA-2 Trial: Mantle Cell Lymphoma
In the ZUMA-2 trial, Kite Pharma is also evaluating the treatment of relapsed/refractory mantle cell lymphoma (MCL) with KTE-C19. MCL...
CAR-T Cell Therapy HCP Guide – KTE-C19 Studies – Zuma 1 Trials
Hematologic Cancers: On Deck for CAR T
Emerging immunotherapies such as chimeric antigen receptor (CAR) T-cell therapies are some of the most exciting new investigational...
StatPearls Question of the Week – #3
From the early clinical trials involving chimeric antigen receptor T cell therapy (CAR-T), cytokine release syndrome has been a major problem. To block the...
